Mark Kendall (engineer)
Mark A. F. Kendall (BE PhD FRSA FTSE) (born 1972) is an Australian biomedical engineer, inventor, scientist and entrepreneur.
Mark Kendall | |
---|---|
Born | 16 April 1972 |
Nationality | Australian |
Occupation | Biomedical engineer |
Employer | Australian National University |
Known for | Biomedical invention |
He is Founder and CEO of WearOptimo Pty Ltd[1] and the Vice-Chancellor's Entrepreneurial Professor at the Australian National University.[2]
Kendall was formerly the Professor of Biomedical Engineering at the University of Queensland, where he led a team at the Australian Institute for Bioengineering and Nanotechnology. He was Founder, CTO and a Director of Vaxxas. Prior to this, in the UK, he was a University Research Lecturer at the University of Oxford and a Lecturer at Magdalen College, Oxford. Whilst at Oxford, Kendall was Associate Director of the PowderJect Research Centre for Gene and Drug Delivery.
Kendall serves at the co-chair of the $150 million Australian Stem Cell Therapies Mission[3] and on the World Economic Forum Global Future Council on Biotechnology.[4]
Kendall has filed more than 160 patents (including territories), published in excess of 300 papers, licensed his technologies seven times (including to Merck & Co.) and partnered globally, including with the World Health Organization, and the Bill & Melinda Gates Foundation.[5] The biotech enterprises he has founded or made significant contribution to have generated in the region of $2 billion Aus in value.
Kendall's contributions to innovation in global healthcare has been recognised with more than forty awards. These include recent elections as:
• World Economic Forum Technology Pioneer (2015).[6]
• Fellow of ATSE; Australian Academy of Technological Sciences and Engineering (2017).[7]
• Fellow of the Royal Society for the encouragement of Arts, Manufacture and Commerce (now the RSA), UK; (2017).
Kendall is a CSL Young Florey Medallist[8] and Rolex Laureate.[9][10][11]
Kendall's work regularly features in international media, including on the National Geographic Channel.[12]
Kendall's TedGlobal talk has been viewed more than a million times.[13]
Background
Kendall was born on April 16th 1972.[14] He received his Bachelors of Engineering (Hons I, 1993) and PhD (1998) from the University of Queensland.[15]
In 1998, Kendall moved to the UK to take up a position in the Department of Engineering Science at the University of Oxford (1998-2006). He has subsequently held positions at the University of Queensland (2006-2018) and at the Australian National University (2018 - Present).
Contributions to Biotechnology
Kendall has over 160 patent applications of which, 128 have been granted to date. He has authored more than 300 refereed papers.
At the University of Oxford[15] (1998-2006) Kendall developed a biolistic technique for the delivery of vaccines directly into the skin without the use of needles.
At the University of Queensland (2006-2018) Kendall invented the Nanopatch[16][17] for needle-free delivery of vaccines.[18][19]
At WearOptimo[20] and the Australian National University[21] (2018 to present), Kendall has invented the Microwearable™ [22][23] sensor for personalised medicine.
During his career, Kendall has collaborated with major global health partners including the Bill & Melinda Gates Foundation,[24] World Health Organization[25][26] and Merck & Co..[27]
He is an Australian Government Academy of Science Covid-19 Expert [28].
Selected Awards, Honours and Prizes
- Elected to the World Economic Forum Global Future Council on Biotechnology (2019 to present).[29]
- Elected Fellow of the Australian Academy of Technology and Engineering ATSE (2017).[30]
- Elected Fellow of the Royal Society for the encouragement of Arts, Manufacture and Commerce (now the RSA), UK (2017).
- Elected to the World Economic Forum Global Future Council on Entrepreneurship and Innovation (2016-2018).
- Dr John Dixon Hughes Medal for Medical Research Innovation (2016).[34]
- World Economic Forum Technology Pioneer (2015).[35]
- Rolex Laureate Award for Enterprise (2012)[36] for his "pioneering efforts to expand knowledge and improve human life".[37]
- 2011 Australian Innovation Challenge winner.[38]
- 2011 Eureka Prize for Interdisciplinary Research.[39]
- 2010 Merck Translational Research Excellence Commercialisation Award.[40]
- 2005 Best Medical Innovation Award (Popular Science magazine).
- Younger Engineer of Great Britain (2004).
Contributions to biotech companies
As Associate Director of the Oxford University PowderJect Research Centre (2000-2006), Kendall advanced biolistics technology, commercialised with PowderJect, purchased by Chiron (later Novartis) in 2003; and then with PowderMed, purchased by Pfizer in 2006.
Kendall founded Vaxxas in 2011 to advance his Nanopatch[41] technology for global impact, securing more than $40 million of investment, in the series A ($15m) [42] and B (in excess of $25m) rounds.[43] The Nanopatch technology has been licensed to Merck & Co. He served as the Vaxxas Chief Technology Officer, Director, and Chair of the Vaxxas Advisory Board (2011-2015).
In 2018, Kendall founded WearOptimo[44] where he serves as CEO.
References
- "Home | WearOptimo | Microwearable devices | Australia". WearOptimo / to edit. Retrieved 8 June 2020.
- "ANU welcomes funding for wearable medical technology". ANU. 16 May 2018. Retrieved 8 June 2020.
- Hunt, Greg (13 March 2019). "Australian Stem Cell Therapies Mission". Retrieved 8 June 2020.
- WEF. "Future of Biotechnology". World Economic Forum. Retrieved 8 June 2020.
- "After 160 years, it's time to move on from the needle and syringe". www.scienceinpublic.com.au. Retrieved 8 June 2020.
- "Authors". World Economic Forum. Retrieved 8 June 2020.
- "Mark Kendall elected as a Fellow of the Australian Academy of Technological Sciences and Engineering (ATSE)". CBNS. 17 October 2017. Retrieved 8 June 2020.
- Australian Institute of, Policy and Science. "Young Florey Medal". Retrieved 9 June 2020.
- "Rolex Awards for Enterprise", Wikipedia, 14 March 2020, retrieved 8 June 2020
- "Fear of Needles? There's New Tech on the Way". National Geographic News. 14 November 2016. Retrieved 8 June 2020.
- "5 Times Rolex Helped to Make the World a Better Place". Time and Tide Watches. 27 September 2016. Retrieved 8 June 2020.
- "Fear of Needles? There's New Tech on the Way". National Geographic News. 14 November 2016. Retrieved 10 June 2020.
- Kendall, Mark. "Mark Kendall | Speaker | TED". www.ted.com. Retrieved 8 June 2020.
- "Mark Kendall: Profile". Rolex Awards for Enterprise. Retrieved 10 June 2016.
- Scott, Leisa (30 November 2013). "Professor Mark Kendall, 41, biomedical engineer/inventor". The Courier-Mail. Retrieved 10 June 2016.
- Council, Australian Research (5 June 2018). "Nanopatch—Revolutionising treatment of disease across the globe". www.arc.gov.au. Retrieved 10 June 2020.
- "UQ technology with the power to revolutionise global vaccine delivery". UniQuest. Retrieved 10 June 2020.
- Vidal, John (26 December 2012). "Vaccine patch offers pain-free way to stop disease in Papua New Guinea | John Vidal". The Guardian. ISSN 0261-3077. Retrieved 10 June 2020.
- ""Nanopatch" Administers Vaccines Painlessly". National Geographic Society Newsroom. 26 November 2012. Retrieved 10 June 2020.
- "About | WearOptimo | Established by Professor Mark Kendall | Brisbane Australia". WearOptimo / to edit. Retrieved 9 June 2020.
- "WearOptimo and ANU: towards a healthcare future within the fourth industrial revolution". ANU. 2 October 2018. Retrieved 8 June 2020.
- "WearOptimo headquarters open in Brisbane". ANU. 29 March 2019. Retrieved 8 June 2020.
- "Our Tech | WearOptimo | Microwearable devises | Australia". WearOptimo / to edit. Retrieved 9 June 2020.
- "Nanopatch Delivery of DNA-Based Malaria Vaccines to Skin: Precisely Targeting the Skin Immune System for Radically Improved Vaccines | Grand Challenges". gcgh.grandchallenges.org. Retrieved 9 June 2020.
- "Nanopatch polio vaccine delivers". ScienceDaily. Retrieved 9 June 2020.
- "Nanopatch creator Mark Kendall". Science Meets Business. 24 April 2017. Retrieved 9 June 2020.
- Council, Australian Research (19 July 2018). "ARC Future Fellow pioneers needle-free immunisation for the world". www.arc.gov.au. Retrieved 9 June 2020.
- "Expert - Mark Kendall | Australian Academy of Science". www.science.org.au. Retrieved 8 June 2020.
- "The Future of Biotechnology". World Economic Forum. Retrieved 10 June 2020.
- "Mark Kendall elected as a Fellow of the Australian Academy of Technological Sciences and Engineering (ATSE)". CBNS. 17 October 2017. Retrieved 8 June 2020.
- "Professor Mark Kendall wins the 2016 CSL Young Florey Medal". CBNS. 11 November 2016. Retrieved 10 June 2020.
- "2016 – Professor Mark Kendall – AIPS". Retrieved 10 June 2020.
- "Media Kit – 2016 CSL Young Florey Medal". www.scienceinpublic.com.au. Retrieved 10 June 2020.
- "Previous Medal Winners - NFMRINFMRI". Retrieved 10 June 2020.
- "4 things Australia needs to know about innovation". World Economic Forum. Retrieved 10 June 2020.
- "Rolex Awards for Enterprise", Wikipedia, 14 March 2020, retrieved 8 June 2020
- "Researchers: Professor Mark Kendall". Australian Institute for Bioengineering and Nanotechnology. Retrieved 10 June 2016.
- Council, Australian Research (19 July 2018). "ARC Future Fellow pioneers needle-free immunisation for the world". www.arc.gov.au. Retrieved 10 June 2020.
- Council, Australian Research (19 July 2018). "ARC Future Fellow pioneers needle-free immunisation for the world". www.arc.gov.au. Retrieved 10 June 2020.
- "Nanotechnology Now - Press Release: Needle-free vaccine technology a step closer to clinical trials". www.nanotech-now.com. Retrieved 10 June 2020.
- Council, Australian Research (5 June 2018). "Nanopatch—Revolutionising treatment of disease across the globe". www.arc.gov.au. Retrieved 10 June 2020.
- Queensl, The University of; Lucia, Australia Brisbane St; Gatton, QLD 4072 +61 7 3365 1111 Other Campuses: UQ; Maps, UQ Herston; Queensl, Directions © 2020 The University of. "New vaccine delivery company starts with AUD15 million investment". UQ News. Retrieved 9 June 2020.
- Queensl, The University of; Lucia, Australia Brisbane St; Gatton, QLD 4072 +61 7 3365 1111 Other Campuses: UQ; Maps, UQ Herston; Queensl, Directions © 2020 The University of. "Nanopatch vaccine technology company attracts $25 million". UQ News. Retrieved 8 June 2020.
- "Home | WearOptimo | Microwearable devices | Australia". WearOptimo / to edit. Retrieved 10 June 2020.